Wang Y T, Poh S C
Aust N Z J Med. 1986 Aug;16(4):496-500. doi: 10.1111/j.1445-5994.1986.tb02020.x.
Thirty-five thyrotoxic patients were assessed before treatment, after treatment with propranolol, and after antithyroid drugs. The first group of patients (n = 17) performed the following tests at all three assessment points: forced expiratory volume in the first second (FEV1), vital capacity (VC), functional residual capacity (FRC), residual volume (RV), total lung capacity (TLC), maximal mid-expiratory flow rate (MMFR), diffusing capacity for carbon monoxide (DLCO), and maximum static inspiratory and expiratory mouth pressures (PImax and PEmax). Arterial blood gas analysis was also performed for the first group of patients. No significant changes were seen either after propranolol or after antithyroid drugs in the FRC, RV, TLC, MMFR, DLCO, or blood gases. The remaining 18 patients, group 2, performed only the FEV1, VC, PImax, and PEmax tests at each assessment. The only index of respiratory function that improved significantly after propranolol was PImax (from 46.5 +/- 16.5 to 53.2 +/- 22 cmH2O, p less than 0.01). This suggests that adrenergic excess may play a role in thyrotoxic inspiratory muscle weakness. After antithyroid drugs, PImax, PEmax, FEV1, and VC all increased significantly as expected.
35例甲状腺毒症患者在治疗前、普萘洛尔治疗后及抗甲状腺药物治疗后接受了评估。第一组患者（n = 17）在所有三个评估点均进行了以下检查：第1秒用力呼气量（FEV1）、肺活量（VC）、功能残气量（FRC）、残气量（RV）、肺总量（TLC）、最大呼气中期流速（MMFR）、一氧化碳弥散量（DLCO）以及最大静态吸气和呼气口腔压力（PImax和PEmax）。第一组患者还进行了动脉血气分析。在使用普萘洛尔或抗甲状腺药物后，FRC、RV、TLC、MMFR、DLCO或血气均未出现显著变化。其余18例患者（第2组）在每次评估时仅进行了FEV1、VC、PImax和PEmax检查。普萘洛尔治疗后唯一显著改善的呼吸功能指标是PImax（从46.5±16.5增至53.2±22 cmH2O，p<0.01）。这表明肾上腺素能亢进可能在甲状腺毒症性吸气肌无力中起作用。使用抗甲状腺药物后，PImax、PEmax、FEV1和VC均如预期显著增加。
